Prognostic value of the X-linked inhibitor of apoptosis protein for invasive ductal breast cancer with triple-negative phenotype

Human Pathology

Volumn 41, Issue 8, 2010, Pages 1186-1195

  Wang, Jinjing ^a   Liu, Yixin ^a   Ji, Ru ^a   Gu, Qiang ^a   Zhao, Xiulan ^a   Liu, Yanrong ^a   Sun, Baocun ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Invasive ductal breast cancer; Triple negative; X linked inhibitor of apoptosis proteins (XIAP)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOLOGY; PATIENT INFORMATION; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR VOLUME; BREAST TUMOR; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PROTEIN MICROARRAY; SURVIVAL;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; PROTEIN ARRAY ANALYSIS; SURVIVAL ANALYSIS; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 77955060064     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.01.013     Document Type: Article

References (35)

1. Zhao J., Liu H., and Wang M. Characteristics and prognosis for molecular breast cancer subtypes in Chinese women J Surg Oncol 100 2009 89 94
2. Munoz M., Fernandez-Acenero M.J., Martin S., and Schneider J. Prognostic significance of molecular classification of breast invasive ductal carcinoma Arch Gynecol Obstet 280 2009 43 48
3. Tang P., Wang J., and Bourne P. Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same? Hum Pathol 39 2008 506 513
4. Akiyama F., and Iwase H. Triple negative breast cancer: clinicopathological characteristics and treatment strategies Breast Cancer 2009
5. Reis-Filho J.S., and Tutt A.N. Triple negative tumours: a critical review Histopathology 52 2008 108 118
6. Miron L., Marinca A., Marinca M., and Miron I. Triple-negative breast cancer-towards a new entity Rev Med Chir Soc Med Nat Iasi 112 2008 51 58
7. Fejerman L., and Ziv E. Population differences in breast cancer severity Pharmacogenomics 9 2008 323 333
8. Callagy G., Cattaneo E., and Daigo Y. Molecular classification of breast carcinomas using tissue microarrays Diagn Mol Pathol 12 2003 27 34
9. Kevans D., Foley J., and Tenniswood M. High clusterin expression correlates with a poor outcome in stage II colorectal cancers Cancer Epidemiol Biomarkers Prev 18 2009 393 399
10. Koo J.S., Jung W., and Jeong J. The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast cancer Jpn J Clin Oncol 39 2009 560 568
11. Shah S.S., Ketterling R.P., and Goetz M.P. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer Hum Pathol 41 2010 103 106
12. Decker T., Hungermann D., and Bocker W. Prognostic and predictive factors of invasive breast cancer: update 2009 Pathologe 30 2009 49 55
13. Vieira D.S., Dufloth R.M., Schmitt F.C., and Zeferino L.C. Breast cancer: new concepts in classification Rev Bras Ginecol Obstet 30 2008 42 47
14. Viale G., Rotmensz N., and Maisonneuve P. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity Breast Cancer Res Treat 116 2009 317 328
15. Agrawal G., Chen J.H., and Baick C.H. Pathological complete response in triple negative poorly differentiated invasive ductal breast carcinoma detected during pregnancy J Clin Oncol 25 2007 2618 2620
16. Wiechmann L., Sampson M., and Stempel M. Presenting features of breast cancer differ by molecular subtype Ann Surg Oncol 16 2009 2705 2710
17. Geyer F.C., Marchio C., and Reis-Filho J.S. The role of molecular analysis in breast cancer Pathology 41 2009 77 88
18. Goncalves A., Charafe-Jauffret E., and Bertucci F. Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes Mol Cell Proteomics 7 2008 1420 1433
19. Kapp A.V., Jeffrey S.S., and Langerod A. Discovery and validation of breast cancer subtypes BMC Genomics 7 2006 231
20. Yagmurdur M.C., Atac F.B., and Tutar N.U. Prognostic value of the PAI-1 4G/5G polymorphism in invasive ductal carcinoma of the breast Int Surg 93 2008 163 168
21. Garcia-Closas M., Brinton L.A., and Lissowska J. Established breast cancer risk factors by clinically important tumour characteristics Br J Cancer 95 2006 123 129
22. Rumble J.M., and Duckett C.S. Diverse functions within the IAP family J Cell Sci 121 2008 3505 3507
23. Mufti A.R., Burstein E., and Duckett C.S. XIAP: cell death regulation meets copper homeostasis Arch Biochem Biophys 463 2007 168 174
24. Paulsen M., Ussat S., and Jakob M. Interaction with XIAP prevents full caspase-3/-7 activation in proliferating human T lymphocytes Eur J Immunol 38 2008 1979 1987
25. Ho A.T., Li Q.H., Okada H., Mak T.W., and Zacksenhaus E. XIAP activity dictates Apaf-1 dependency for caspase 9 activation Mol Cell Biol 27 2007 5673 5685
26. Sun Y., Qiao L., and Zou B. Interactions between XIAP associated factor 1 and a nuclear co-activator, CBP, in colon cancer cells Digestion 77 2008 79 86
27. Emanuel P.O., Phelps R.G., Mudgil A., Shafir M., and Burstein D.E. Immunohistochemical detection of XIAP in melanoma J Cutan Pathol 35 2008 292 297
28. Li M., Song T., Yin Z.F., and Na Y.Q. XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer Chin Med J (Engl) 120 2007 469 473
29. Schimmer A.D., and Dalili S. Targeting the IAP family of caspase inhibitors as an emerging therapeutic strategy Hematology Am Soc Hematol Educ Program 2005 215 219
30. Mizutani Y., Nakanishi H., and Li Y.N. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis Int J Oncol 30 2007 919 925
31. Liu J., Li M., and Xia S. Expression and clinical significance of antiapoptosis gene XIAP in prostate cancer Zhonghua Nan Ke Xue 10 2004 832 835
32. Shibata T., Noguchi T., Takeno S., Gabbert H.E., Ramp U., and Kawahara K. Disturbed XIAP and XAF1 expression balance is an independent prognostic factor in gastric adenocarcinomas Ann Surg Oncol 15 2008 3579 3587
33. Tiezzi D.G., de Andrade J.M., Marana H.R., Garieri A.P., and de Paula Philbert P.M. Clinical criteria as predictive factors of response to primary hormone therapy in locally advanced breast cancer Breast J 15 2009 333 338
34. Wiesner F.G., Magener A., and Fasching P.A. Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients Breast 18 2009 135 141
35. Tambo M., Higashihara E., Terado Y., Nutahara K., and Okegawa T. Comparison of serum HER2/neu with immunohistochemical HER2/neu expression for the prediction of biochemical progression in metastatic prostate cancer Int J Urol 16 2009 369 374